Baylor Genetics’ Rapid Whole Genome Sequencing Enables Earlier, More Comprehensive Diagnoses for Infants with Cardiac Indications
A retrospective analysis presented by Baylor Genetics at the 2026 ACMG Annual Meeting showed that rWGS delivered at least one diagnosis for nearly one in four critically ill infants with cardiac indications, often with a median turnaround time of five days. The findings underscore the value of rWGS testing in high-acuity neonatal settings, allowing for more timely and informed clinical management.